A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Haeseong ParkKerry WilliamsNikolaos A TrikalinosSarah LarsonBenjamin TanSaiama WaqarRama SureshDaniel MorgenszternBrian A Van TineRamaswamy GovindanJingqin LuoA Craig LockhartAndrea Wang-GillamPublished in: Cancer chemotherapy and pharmacology (2020)
The combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263).